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Abstract
Background. Diabetes is a significant risk factor for peripheral artery disease. Individuals with
diabetes, greater than 50 years of age, having at least one other risk factor should be screened for
peripheral artery disease with an ankle brachial index. Purpose. Improve detection and
management of peripheral artery disease in persons with diabetes within primary care. Evidence.
Individuals with diabetes and peripheral artery disease have an increased risk of adverse cardiac
and limb events, impairing the patient’s quality of life and causing long-term disability (Berger
& Newman, 2020). Methods. During a 10-week period, these processes were implemented: (a)
screening all patients with diabetes for peripheral artery disease risk factors; (b) conducting ankle
brachial indexes for those with risk factors; (c) assessing for statin and antiplatelet medication
coverage; (d) providing diet, exercise, and smoking cessation counseling; (e) referring patients
with abnormal results for vascular evaluation. Results. 257 (83%) patients were high-risk for
peripheral artery disease and needed ankle brachial index screening. A total of 23 ankle brachial
indexes were completed with 3 abnormal tests requiring referrals. Of the 257 evaluated,
antiplatelet therapy was utilized by 172 (67%) while statin therapy was utilized by 223 (86.7%).
Education was provided to 110 of the patients. Fourteen of those were active smokers. Barriers
included staffing issues and the COVID pandemic. Implications. Results emphasize the
importance of screening and evaluating all patients with diabetes for peripheral artery disease
risk factors and implementing comprehensive guidelines. For sustainment, consideration must be
given to same-day ankle brachial index testing.
Keywords: ankle brachial index, peripheral artery disease, type 2 diabetes
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Improving the Early Detection and Management of Peripheral Artery Disease
in Patients With Diabetes Within the Primary Care Setting
Peripheral artery disease (PAD) is known to be widely underdiagnosed in the primary
care setting. It is estimated that only 10% of those diagnosed with PAD endorse the classic
symptom of intermittent claudication (Virani et al., 2020). The remaining individuals either have
no leg pain or have various leg symptoms related to exertion that is not always enough to inhibit
their physical activity (Virani et al., 2020). Its prevalence increases with age as well as
possessing risk factors such as smoking, diabetes mellitus (DM) type 2, hypertension, and
hypercholesterolemia (Virani et al., 2020). During the conduction of the microsystem
assessment, it was noted that there was a need for a standardized approach in screening patients
for PAD. Regular screening for PAD varies amongst clinical settings and is many times
dependent on patients being symptomatic. Current evidence supports the use of the anklebrachial index (ABI) as a diagnostic test for PAD. The ABI is useful in detecting PAD in both
asymptomatic and symptomatic patients. This project focuses on improving the early detection
and management of PAD in the diabetic population within the primary care setting through the
implementation of a screening tool to identify patients at risk, screening patients determined to
be a risk with a digital ABI device and utilizing evidence-based preventative measures to slow
the progression of the disease in those identified to be high-risk.
Current Guidelines
The American College of Cardiology (ACC), American Heart Association (AHA), and
the U.S. Preventive Services Task Force (USPSTF) outline several recommendations for the
management and care of patients with PAD. The recommendations from these organizations
were categorized based on the strength of the evidence in relation to patient risk and benefit
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using the ACC/AHA Clinical Practice Guideline Recommendation Classification System. ABI is
recommended as a diagnostic tool to establish the diagnosis of PAD when patient history or
physical examination findings are suggestive of PAD (Gerhard-Herman et al., 2016). Results
should be reported as abnormal (ABI ≤0.90), borderline (ABI 0.91–0.99), normal (1.00–1.40), or
noncompressible (ABI >1.40). It is reasonable to obtain an ABI on patients who are noted to
have increased risk factors of developing PAD but do not have history or physical examination
findings suggesting PAD (Gerhard-Herman et al., 2016).
The use of aspirin 75-325 mg per day or clopidogrel 75 mg per day is recommended to
reduce myocardial infarction (MI), stroke, and vascular death in patients who have symptomatic
PAD. The use of antiplatelet therapy is reasonable for those who have asymptomatic PAD to
reduce their risk of MI, stroke, or vascular death (Gerhard-Herman et al., 2016). The benefits of
using antiplatelet therapy in those with borderline ABI is uncertain (Gerhard-Herman et al.,
2016).
Other therapies that are recommended for patients who have PAD include statin therapy,
antihypertensive therapy, control of DM, and cessation of smoking. The use of statin therapy is
indicated for all patients with PAD (Gerhard-Herman et al., 2016). Antihypertensive therapy
should be administered to those with hypertension and PAD to reduce risk of MI, stroke, heart
failure, and cardiovascular death (Gerhard-Herman et al., 2016). Patients with PAD and DM
should be managed by members of the healthcare team to control glucose levels and reduce
complications associated with uncontrolled DM (Gerhard-Herman et al., 2016). Patients
diagnosed with PAD who smoke, vape, or use any tobacco products should be advised to quit
smoking, vaping, or using any form of tobacco at every visit (Gerhard-Herman et al., 2016).
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Statement of the Problem
During a microsystem assessment of my clinical site, it was noted that there was not a
standardized approach in screening patients for PAD, particularly among patients with diabetes.
The clinic had also identified this as an issue but was in the preliminary process of establishing a
protocol whereby the providers would evaluate patients for PAD, although no formal process had
been approved or implemented. Earlier in 2020, the clinic purchased a digital ABI device from
QuantaFlo as a diagnostic tool to help identify patients with decreased vascular flow secondary
to PAD. However, the clinic had neither established any clinical practice guidelines for how to
evaluate patients for PAD nor identified what interventions would be included in the plan of care
for patients once PAD was diagnosed. My assessment of the clinical site revealed that the clinic
was only using the ABI for patients presenting to the clinic with symptoms of PAD or if a
patient’s health insurance specifically requested the ABI testing.
The prevalence of PAD is widely underestimated in the diabetic population and can be
attributed to patients being asymptomatic or symptoms being attributed to diabetic neuropathy
(Berger & Newman, 2020). This delay in diagnosis of PAD increases a patient’s risk of
developing adverse cardiac and limb events, impairing the patient’s quality of life, and causing
long-term disability (Berger & Newman, 2020).
Shortly after the clinic obtained the QuantaFloTM ABI device, the coronavirus-19
(COVID-19) pandemic caused the clinic to shift from face-to-face office visits to utilizing
telemedicine as the primary healthcare delivery method for all patients, which further limited
assessing ABI indexes. The urgent need to develop protocols for seeing patients via telemedicine
further delayed the clinic in developing any clinical protocols for assessing ABI indexes and
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identifying which interventions should be included in the treatment plan of patients who had
significant altered vascular flow.
A large portion of the patient population seen at this clinic has a diagnosis of DM type 2,
which has been identified as a significant risk factor for PAD. One-third of those diagnosed with
PAD have DM (Berger & Newman, 2020). The AHA and ACC have identified that those
individuals age 50 and older with DM who have one additional risk factor for atherosclerosis,
such as a history of smoking, hyperlipidemia, or hypertension, are at an increased risk of
developing PAD (Gerhard-Herman et al., 2016). In many cases, the damage done by PAD is
irreversible. Establishing regular screening for PAD in patients with DM will improve the early
detection of PAD and reduce the risk of stroke, MI, and amputation of the lower extremities
(Virani et al., 2020). The diagnosis of PAD can be made by measuring the ABI. There are
currently two methods that can be used to assess ABI. These include manually assessing ABI or
using a digital ABI system.
Background and Significance
More than 170 million people worldwide have DM, and the number is growing every
year (Berger & Newman, 2020). One-third of those diagnosed with PAD have DM (Berger &
Newman, 2020). DM is a significant risk factor for PAD. Those with DM and PAD have an
increased risk of adverse cardiac and limb events, impairing the patient’s quality of life and
causing long-term disability (Berger & Newman, 2020). The prevalence of PAD is widely
underestimated in the diabetic population and can be attributed to patients being asymptomatic or
symptoms being attributed to diabetic neuropathy (Berger & Newman, 2020). Risk factors for
PAD include advanced age, smoking, hypertension, dyslipidemia, and coronary heart disease, in
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addition to DM (Berger & Newman, 2020). A patient’s DM duration, DM severity, sex, and
race/ethnicity also play a role in the risk of PAD (Berger & Newman, 2020).
The diagnosis of PAD is made using the measurement of the ankle-brachial index.
Typically, this is done manually by comparing the highest systolic blood pressure of the
posterior tibial or dorsalis pedis artery in each leg divided by the highest systolic pressure of the
right and left brachial artery. This method can be time-consuming and subject to user error,
depending on the operator (Gajanana et al., 2019). A digital ABI system can be used as a
valuable, simple, cost-effective, and reliable screening tool with high sensitivity and accuracy
(Gajanana et al., 2019). A digital ABI is performed by placing the patient in a supine position
with their arms and legs at the same level as their heart. The optical sensor is placed sequentially
on one of the fingers on the right and left hand and on one of the toes on the right and left foot. It
takes approximately 15 s to obtain a waveform on each digit. At the completion of the 60 s, a
report will be generated. The ABI results are then interpreted by the provider.
Currently, the clinic uses their ABI device on an as needed basis. Most of the time, the
digital ABI QuantaFloTM is utilized to obtain an ABI on patients at the request of the patients’
insurance companies. This is per the specific insurance protocols for patients with diabetes and
patients without diabetes that have cardiovascular risk factors. The pandemic impacted the
ability of the clinic to conduction ABI testing even when the insurance company required ABI
testing since the clinic was only seeing their patients via telemedicine for several months and had
only recently began seeing patients in the office on a regular basis in conjunction with the
continued use of telemedicine.
The provider prescribes statins, antiplatelets, and antihypertensives to patients with
diabetes at risk for PAD inconsistently. The majority of the patients who are prescribed these
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medications require them for other medical conditions. Patient education specific to smoking
cessation and dietary counseling is provided to patients who smoke and/or who are obese at the
time they first join the clinic and initiate care. This patient education is also provided to patients
newly diagnosed with diabetes. It is not regularly addressed or discussed after this initial visit
unless the provider identified a specific reason to address it again. Prior to the project’s
implementation, these patients were receiving inconsistent preventative care and were not being
screened for potential PAD risk.
Assessment
The internal medicine clinic has two locations, one on the south side of San Antonio and
the other in Somerset, Texas. Both locations serve a multiracial and multicultural population.
The clinics were equipped to provide a multitude of services including routine primary care,
preventative medicine, industrial examinations, general health physicals, and chronic care
management. The physician is the owner and primary operator of the clinics. Staff in the clinics
includes one physician, two receptionists, four medical assistants (MA), one office manager, one
quality manager, and one billing clerk. The physician used a systematic approach to disease
management and preventative medicine using pre-developed care plans created by the physician.
The clinics see on average 20-30 patients a day between both locations. The physician allots 1530 min per patient depending on the patient’s reason for the office visit. The staff ensure that
appointments are properly scheduled. Ethnicity was inconsistently documented by the clinic. If a
patient did not list their ethnicity on the new patient paperwork at their first visit, then it was left
blank in the patient’s electronic record and was not addressed further. Based on direct clinical
observation, most patients were Hispanic between the ages of 40-79 years. Males accounted for
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54.5% of the population. Table 1 provides details about patient demographics from my clinical
assessment.
Table 1
Patient Demographics From Clinic Assessment
Characteristics

Percentage

Age Group
20-29 years

0.99%

30-39 years

3%

40-49 years

14%

50-59 years

21%

60-69 years

32%

70-79 years

24%

80-89 years

5%

90-99 years

0.01%

Gender
Male

54.5%

Female

45.5%

Ethnicity
Hispanic

72%

Black

1%

White

26%

Other

1%

The top diagnoses observed in the clinic and reported by the provider included
hypertension, hyperlipidemia, and DM. These direct observations were made during my onsite
assessment, as the clinic does not have the ability to pull this data within their electronic system.
The physician accepts a variety of medical insurances including Health Maintenance
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Organizations plans, Affordable Care Act plans, Medicare Advantage plans, Preferred Provider
Organizations plans, Medicare and Medicaid, and private insurance plans.
Currently, the clinics do not have a systematic approach to screen and treat patients for
PAD. Before obtaining the digital ABI machine, the clinics would perform the traditional manual
ABI on patients who displayed symptoms consistent with intermittent claudication and refer
them to a vascular specialist when necessary, as determined by the physician. No specific
screening was done for patients with DM who presented to the clinic. Any preventative measures
were initiated based on the physician’s recommendation after reviewing the electronic medical
record (EMR) and performing an examination.
It is difficult to track what preventative measures were initiated for patients with DM who
were identified as being at risk for PAD because the clinic does not have a way to extract this
type of data in a reliable and consistent manner. For this reason, the use of a pre-developed plan
of care is essential in ensuring that all patients receive standardized care that can be easily
followed and monitored. The process created for this project ensures that screening,
management, risk reduction, and referrals are all addressed as part of the pre-developed plan of
care.
During the microsystem assessment, it was noted that there was a need for a standardized
approach in screening patients for PAD and providing preventative measures to reduce patients’
risk of developing PAD complications. Any delay in diagnosis of PAD increases patients’ risk of
developing a MI, stroke, and/or vascular death (Gerhard-Herman et al., 2016). The clinic
provided evidence-based interventions to their patients with diabetes including the initiation of
antiplatelet therapy, statin therapy, diet counseling, exercise counseling, and smoking cessation
counseling for those patients identified at risk for PAD, but these measures were not done
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regularly, consistently, and varied from patient-to-patient dependent on their insurance coverage,
the patient’s receptiveness to treatment, and the patient’s regularity of follow up care. No
specific process was in place prior to the project’s implementation to ensure that patients with
DM were receiving regular screening for PAD. Those patients who were currently receiving
regular ABI screenings were patients with WellMed coverage. WellMed requires regular ABI
screening as part of its wellness protocols every 3 years for those at risk for PAD or peripheral
vascular disease (PVD) that have not yet been diagnosed with PAD or PVD. I determined that
the clinics had the capability to conduct diagnostic testing for PAD using the ABI index but
lacked uniformity in implementing current clinical practice guidelines. It was interesting to note
that most of the MAs had a basic understanding of the QuantaFloTM device, but the MAs
identified the need for a refresher course when asked about their comfort level using the
equipment and their knowledge related to performing the procedure.
Organization’s Readiness for Change
The physician and a majority of the clinic staff expressed a readiness for change in
implementing a routine screening process for PAD in patients with DM, assessing ABI for
patients identified to be at risk for PAD, and implementing risk reduction interventions. Some of
the MAs expressed their discomfort with handling feet which could have impacted their level of
cooperation and consistency in implementing the protocols. This was of particular importance to
the project’s success as the MAs played a pivotal role in ensuring that all interventions were
carried out from the time the patients checked-in for the office visits until the patients checked
out with the receptionist. Despite the MAs’ initial hesitation, they were willing to implement the
clinical practice guidelines that were developed for this project. The physician, who is the
primary driver of change for the clinic, expressed his willingness to participate in the project and
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showed interest in adopting the proposed interventions as part of the pre-developed care plan for
those patients with DM who are at risk for PAD. The physician’s participation in the project also
allowed him to provide valuable feedback to the sustainability of the project and its effect on
patient outcomes. The rest of the support staff including the office manager and the quality
manager all expressed an interest in the project and provided their support throughout the
development and implementation of the project. The physician and staff were well aware of the
implications this project played related to patient outcomes. Their dedication and devotion to
their patients inspired them to do their part to better the lives of others. A letter of support for
implementing this project was obtained from my clinic mentor who also serves as the provider
for the clinic (Appendix A).
Stakeholders and Stakeholders Engagement
The quality manager meets with various insurance providers quarterly to review and
discuss quality metrics either virtually or by teleconference. Depending on the provider, the
metrics discussed include utilization of statins, aspirin, angiotensin converting enzyme (ACE)
inhibitors, diabetes control based on patients’ hemoglobin A1C, and the completion of ABI
testing. Interventions to improve each metric are occasionally discussed during these meetings.
Reports can be regularly generated and printed to track the clinic’s progress. The metrics are tied
directly to the clinic’s reimbursement and performance rating. Therefore, there is a financial
incentive for the clinic to be implementing the recommended clinical guidelines for management
of patients with diabetes in order to prevent complications associated with PAD.
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Project Identification
Purpose
The purpose of this project is to improve the early detection and management of PAD in
patients with DM within the primary care setting following the clinical practice guidelines
outlined by the AHA and ACC for PAD. This included the implementation of a screening tool to
identify patients at risk, the use of a digital ABI device for patients determined to be at risk of
PAD, and implementation of evidence-based preventative measures to slow the progression of
PAD and reduce the risk of complications associated with PAD.
Goals/Objectives
The objectives for this project were:
1.

Increase the number of patients with DM screened for risk factors of PAD from 0%
to 70% within 10 weeks.

2. Increase the utilization of ABI testing for patients with DM that have a risk factor for
PAD from 0% to 50% in 10 weeks.
3. Increase the utilization of statins for patients with decreased ABI and elevated lowdensity lipids as a risk reduction strategy for PAD in patients with DM from 73% to
90% in 10 weeks.
4. Increase the utilization of antiplatelet therapy in patients with decreased ABI as a risk
reduction strategy for PAD in patients with DM from 49% to 75% in 12 weeks.
5. Increase diet and exercise counseling amongst patients with a decreased ABI and DM
from 0% to 75% in 10 weeks.
6. Increase the provision of smoking cessation education to patients with a decreased
ABI and DM who are active smokers from 0% to 100% in 10 weeks.

PERIPHERAL ARTERY DISEASE DETECTION & MANAGEMENT

19

7. Increase the referral of patients with DM that have an abnormal ABI > 1.4 or <0.8 to
a vascular specialist from 0% to 100% within 2 weeks of testing (Stanford
Medicine 25, 2020).
Anticipated Outcomes
The anticipated aims were as follows:
1. All staff members will receive education on PAD process, screening tool utilization,
and ABI testing by February 5th, 2021.
2. By April 16, 2021, 100% of all patients with diabetes will be screened for PAD risk
using the screening tool developed for this project.
3. By April 16, 2021, 50% of all patients with diabetes found to be at risk for developing
PAD will have ABI testing completed.
4. By April 16, 2021, 100% of all patients with diabetes found to have an abnormal ABI
>1.4 or <0.8 will be referred to a vascular specialist.
Summary and Strength of the Evidence
PAD is a global health issue that is associated with impaired quality of life, impaired
functional capacity, and increased risk of major adverse cardiovascular and limb events. The
burden associated with this disease process is only expected to increase with changing risk factor
profiles and an aging population (Parvar et al., 2018). A review of the literature was completed
using key search terms in the following databases: CINAHL, PubMed, Cochrane Library, and
UpToDate. Keywords used to focus the search results were ABI, PAD, and type 2 diabetes. The
level and strength of the evidence was scored using the Melnyk and Fineout-Overholt (2015)
system. This system consists of seven levels and is based on a combination of quality, validity,
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and applicability of the evidence to a specific patient environment (Melnyk & Fineout-Overholt,
2015). Table 2 provides a summary overview of the rating system.
Table 2
Level of Evidence
Level of Evidence

Study Design

I

Systematic reviews and meta-analysis of randomized controlled studies

II

Single, randomized controlled studies

III

Quasi-experimental studies and non-randomized controlled studies

IV

Cohort or case-control studies

V

Systematic review or meta-synthesis of qualitative or descriptive
studies

VI

Single, qualitative or descriptive studies

VII

Expert opinion of authorities and/or reports of expert committees

The quality of the evidence was evaluated using the Johns Hopkins Nursing EvidenceBased Practice system (Dang & Dearholt, 2018). This system consists of four levels and uses a
lettering system of A, A-B, B, and C to depict quality of evidence. The quality of evidence is
based on a combination of study design, sample size, scientific evidenced reviewed,
appropriateness of recommendations, and generalizability (Dang & Dearholt, 2018). Table 3
provides a summary of the rating system for quality of evidence.
A total of 21 articles were used for an in-depth synthesis of the literature for this project.
Appendix B outlines the evidentiary table and rating of the evidence for this project. Specific
guidelines for PAD management can be found through the AHA and the ACC (Gerhard-Herman,
et al., 2016) as well as the American Diabetes Association (ADA) (2020). The AHA/ACC
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Quality of Evidence
Quality of Evidence

Criteria

A

High: Conclusive, consistent, sufficient, generalizable; sufficient
sample size for study design; adequate control, definitive
conclusions, consistent recommendations based on comprehensive
literature review that includes thorough references to scientific
evidence.

A-B

High-Good: Fairly conclusive, consistent, sufficient evidence.
Meets some criteria from both A and B levels.

B

Good: Reasonably conclusive, consistent results, sufficient sample
size for study designs; reasonably consistent recommendations
based on fairly comprehensive literature review that includes
references to scientific evidence. However, there may be some
conflicting evidence.

C

Low: Inconclusive, inconsistent, insufficient evidence, insufficient
sample size for the study design, inconsistent results, little
references to scientific evidence. Conclusions cannot be drawn.

21
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outlines in detail prevalence, incidence, risk factors, genetics, awareness, treatment, control,
mortality, complications, healthcare utilization, and global burden of PAD (Virani et al., 2020).
Globally, 202 million people had PAD between 2000-2010. An increase of 28.7% was seen in
the low to middle income countries and 13.1% in high income countries (Virani et al., 2020).
Smoking, type 2 diabetes, hypertension, and hypercholesterolemia account for the most common
risk factors associated with PAD (Virani et al., 2020). The atherosclerosis risk in communities
(ARIC) study revealed that PAD was higher among participants with lower household income
and educational attainment. Several randomized and observational studies demonstrated that
statins reduced the risk of major adverse cardiovascular events and amputation among people
with PAD as outlined in the 2016 AHA/ACC Guideline on the Management of Patients with
Lower Extremity Peripheral Artery Disease (Gerhard-Herman et al., 2016). As stated by the
AHA/ACC, patients with PAD should receive comprehensive care to include structured exercise
and lifestyle modifications. Smoking cessation is a vital component of care. Pharmacotherapy
should be guideline based with a goal to reduce cardiovascular ischemic and limb-related events.
Antiplatelet therapy with aspirin 75-325 mg per day alone is recommended to reduce MI, stroke,
and vascular death in patients with symptomatic PAD (Gerhard-Herman et al., 2016). Limited
evidence exists to support the use of antiplatelet therapy use in patients with asymptomatic PAD
or in those at high risk of developing PAD. This does not rule out the possibility that aspirin
could provide benefit in such patients (Gerhard-Herman et al., 2016). Statin therapy is indicated
for all patients with PAD as it has been found to improve both cardiovascular and limb outcomes
in patients with PAD. The heart protection study revealed that simvastatin 40 mg daily reduced
the rate of first major vascular event by 22% relative to placebo (Gerhard-Herman et al., 2016).
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In a multinational registry, statin use among these patients reduced 4-year adverse limb-related
events compared with no statin (Gerhard-Herman et al., 2016).
PAD
PAD results from the buildup of plaque in the walls of the arteries thereby reducing blood
flow to the limbs (Johns Hopkins Medicine, 2021). The reduction in blood flow decreases
oxygen and nutrients available to the tissues. The resulting inflammation along with decrease in
blood flow increases the likelihood that blood clots will form in the walls of the arteries leading
to a reduction in the size of the blood vessels and an increase in the potential blockage of the
arteries (Johns Hopkins Medicine, 2021). This prevalent atherosclerotic syndrome is increasing
due to an aging population and an increased prevalence of risk factors with an estimated 200
million people effected worldwide (Berger & Ladapo, 2017). Those with PAD have a two to six
times greater risk of developing cardiovascular and cerebrovascular events compared to those in
the general population of the same age (Parvar et al., 2018). Goals of PAD treatment include
reducing modifiable risk factors and prevention of cardiovascular events followed by guideline
directed therapy that revolves around cardioprotective pharmacotherapies and lifestyle
counseling for healthy behaviors. Studies have shown that the use of well proven
cardioprotective medication therapies for secondary prevention in PAD patients lags
significantly behind similar treatments for coronary artery disease (Berger & Ladapo, 2017).
This is surprising as PAD is a coronary artery disease equivalent.
PAD in Patients With DM
More than 170 million people worldwide have DM and the number is growing every year
(Berger & Newman, 2020). DM is a significant risk factor for developing PAD. Patients
diagnosed with DM and PAD have an increased risk of adverse cardiac and limb events such as
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MI, stroke, or vascular death that can impair the patient’s quality of life and cause long-term
disability (Berger & Newman, 2020). It is interesting to note that only one-third of those
diagnosed with PAD have DM (Berger & Newman, 2020). Many healthcare providers believe
that the prevalence of PAD in patients with DM is under reported because numerous patients
with DM may have no symptoms of PAD and therefore are not screened for PAD or symptoms
were attributed to other causes rather than PAD. Berger and Newman (2020) support this notion
by stating that the prevalence of PAD is widely underestimated in patients with DM and can be
attributed to patients being asymptomatic or with symptoms being attributed to diabetic
neuropathy. The underlying metabolic abnormalities found in patients with DM, “enhance
vascular inflammation, endothelial dysfunction, vasoconstriction, platelet activation, and
thrombotic risk, processes important to the pathogenesis of PAD among patients with DM”
(Berger & Newman, 2020, para. 17). The duration of a patients’ DM, severity of the DM, and
race/ethnicity of the patient also play a role in increasing the risk of PAD risk. African
Americans and Hispanics with DM are known to “have a higher prevalence of PAD compared to
non-Hispanic whites” (Berger & Newman, 2020, para.13).
The United Kingdom Prospective Diabetes Study revealed that each 1% increase in
glycated hemoglobin (HbA1C) was associated with a 28% increase in incidence of PAD (Parvar
et al., 2018). Those with PAD and diabetes are more likely to develop worsening lower extremity
function, arterial thrombosis, and ischemic ulceration compared to those with PAD alone (Parvar
et al., 2018). The pathophysiologic process of diabetes has contributed to a 5-to-10-fold increase
in the likelihood of a major lower limb amputation (Parvar et al., 2018). A study found that 83%
of those older than 70 years of age or those between 50-69 years of age with a known history of
diabetes or smoking with a previous diagnosis of PAD were unable to recognize the diagnosis.
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Of these, only half of their physicians were even aware of the diagnosis of PAD (Virani et al.,
2020).
Screening for PAD
There is limited evidence on methods for screening patients for PAD. Per the AHA/ACC
2016 clinical practice guidelines, evaluating patients for PAD begins with a obtaining a complete
health history, reviewing symptoms, and performing a physical examination. Patients at an
increased risk of developing PAD include those greater than 50 years of age with risk factors for
atherosclerosis that may include diabetes, history of smoking, hyperlipidemia, hypertension, or
family history of PAD (Gerhard-Herman et al., 2016). One study conducted in Hungary revealed
that the implementation of a complex screening program at the general practitioner level makes
the diagnosis of PAD easier, which can lead to earlier identification and management thus
improving the patients’ quality of life and life expectancy (Tóth-Vajna et al., 2019). Smoking,
diabetes type 2, hypertension, and hypercholesterolemia accounted for 75% of risk associated
with PAD amongst men (Virani et al., 2020).
ABI Testing
The diagnosis of PAD can be made when a patient’s history reveals risk factors or
symptoms of PAD and physical examination findings suggest an increased risk for PAD. The
ABI has been recommended as a first line test in the diagnosis of PAD due to its validity
(Gerhard-Herman et al., 2016). Measurement of resting ABI is reasonable in patients at risk for
developing PAD but present without history or physical examination findings that suggest the
diagnosis (Gerhard-Herman et al., 2016). Traditional ABI is determined by comparing the higher
systolic blood pressure in the posterior tibial artery or the dorsalis pedis artery of each leg
divided by the higher systolic blood pressure of the brachial artery in the corresponding right or
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left arm. These pressures are obtained by using a sphygmomanometer and stethoscope to assess
the pressures manually (John Hopkins Medicine, 2021). This method is time-consuming and
subject to user error. Digital ABI on the other hand can be used as a valuable, simple, costeffective, and reliable screening tool with high sensitivity and accuracy (Gajanana et al., 2019).
The digital ABI can be conducted by anyone who has been trained to use the equipment. The
patient ideally should be placed in a supine position with his/her arms and legs at the same level
as his/her heart. The optical sensor should be placed sequentially on one of the fingers of the
right hand and the left hand as well as on one of the toes of the right foot and the left foot. It
takes approximately 15 s to obtain a waveform on each digit. At the completion of 60 s, a report
is generated with the ABI results to be interpreted by the provider (Schaefer, Long, & Pollick,
2016). Vascular imaging is not necessary to diagnose PAD but can help differentiate PAD from
other etiologies related to the vasculature (Neschis & Golden, 2020). Resting ABI results should
be reported as either abnormal (<0.90), borderline (0.91-0.99), normal (1.00-1.40) or
noncompressible (>1.40) (Gerhard-Herman et al., 2016).
Risk Factors for PAD
Risk factors for PAD include advanced age, smoking, hypertension, dyslipidemia,
coronary heart disease, and DM (Berger & Newman, 2020). While there is no way to reduce the
risk of PAD associated with advanced age, there are medical therapies and lifestyle behavior
counseling methods that can reduce the incidence of PAD and cardiovascular events associated
with PAD due to modifiable risk factors. These medical therapies and lifestyle behavior
counseling methods include the use of antiplatelet medications, statins, angiotensin converting
enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs), diet counseling, exercise
counseling, and smoking cessation counseling (Berger & Ladapo, 2017). Studies have
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demonstrated that risk factors such as smoking, hypertension, hypercholesterolemia, and diabetes
significantly increase PAD risk particularly when more than one modifiable risk factor is present
(Newman et al., 2017). Smoking increases PAD occurrence by 2-6 times and increases further
based on the number of cigarettes smoked daily and the number of years the individual has
smoked (Tóth-Vajna et al., 2019). Patients with diabetes have 2.4 times greater risk of
developing PAD and critical limb ischemia than those individuals without diabetes (Tóth-Vajna
et al., 2019). Amputation is five times higher for patients who have developed PAD (Tóth-Vajna
et al., 2019). Hypertension is a significant risk factor for PAD although it is more prevalent in
coronary diseases (Tóth-Vajna et al., 2019). Presence of dyslipidemia was found in 55% of those
with PAD.
Antiplatelet Therapy to Reduce the Risk of PAD
Antiplatelet agents are a mainstay in secondary prevention to reduce adverse
cardiovascular events, yet patients with PAD are often under prescribed these agents. This can be
attributed to the various clinical practice guideline recommendation available to medical
providers. Two trials studied the effect of aspirin on the outcomes in patients with asymptomatic
PAD. The prevention of progression of arterial disease and diabetes (POPADAD) trial enrolled
patients with an ABI of less than or equal to 0.99 who had diabetes and found that there was no
difference in the risk of cardiovascular events or amputation between those taking aspirin and
those who were given the placebo (Hussain et al., 2018). The aspirin for asymptomatic
atherosclerosis study enrolled patients with an ABI less than or equal to 0.95. An average follow
up of 8.2 years revealed no significant difference between those given aspirin and those who
were given the placebo. Those with an ABI less than or equal to 0.09 showed no benefit in the
utilization of aspirin (Hussain et al., 2018). The antithrombotic trialists’ collaboration revealed
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that antiplatelet use was associated with a 23% reduction in serious vascular events (Hussain et
al., 2018). A limitation of this study is that it was conducted 20 years ago and compared several
types of antiplatelets in addition to aspirin. The critical leg ischaemia prevention study examined
both asymptomatic and intermittent claudication randomly and found that aspirin significantly
reduced the risk of cardiovascular events and limb ischemia (Hussain et al., 2018). Overall, the
data regarding the use of aspirin in PAD is inconclusive and this is the reason why the U.S. Food
and Drug Administration has not approved aspirin as therapy specifically for PAD (Hussain et
al., 2018). However, due to the increased risk of adverse cardiovascular events in asymptomatic
PAD, aspirin is a reasonable therapy particularly when another vascular bed is involved (Hussain
et al., 2018). When patients have symptomatic PAD, aspirin or clopidogrel is indicated (Hussain
et al., 2018).
Statin Therapy to Reduce the Risk of PAD
Current practice guidelines from multiple professional societies such as the AHA, ACC,
and the European Society of Cardiology recommend statin therapy for all individuals with PAD
based on studies that have evaluated coronary artery disease (Crismaru & Diaconu, 2015). The
heart protection study compared oral simvastatin 40 mg daily to a placebo over an average of 5
years. Overall, statin utilization was associated with a 16% relative risk reduction in vascular
events and a 20% reduction in noncoronary revascularization (Aday & Everett, 2018). This
included both lower extremity arterial procedures and carotid interventions. Rates of amputations
did not differ between the groups. The reduction of atherothrombosis for continued health
(REACH) registry revealed a “14% relative risk reduction in a composite end point that included
worsening claudication, critical limb ischemia, peripheral revascularization, and amputation at 4
years” (Aday & Everett, 2018, p.1435). Statin intensity has not yet been addressed in relation to
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limb outcomes nor overall mortality benefit (Aday & Everett, 2018). Aday and Everett (2018)
reported on a study that compared statin intensity for those patients who were prescribed statins
to those who were not prescribed statins but who were prescribed antiplatelet agents such as
aspirin. A total of 155,647 patients with PAD were followed for 5.9 years. It was noted that 28%
(45,503) of these patients were not prescribed statins at the time of their diagnosis despite being
at high risk. This was found to be consistent from between 2006 to 2014. Low to moderate dose
statins was associated with a 17% reduction in mortality and a 19% reduction in amputation
compared to the high dose statin that was associated with a 26% reduction in mortality and a
33% reduction in the risk of amputation (Aday & Everett, 2018). This study was observational
and included various limitations that could have accounted for the differences in clinical
outcomes. Despite these limitations, this study adds to growing literature identifying the
underutilization of statin therapy in patients with PAD and speaks to the role that dose intensity
plays in risk reduction.
Statins have not only shown to stabilize and regress atherosclerotic plaques but also have
been found to reduce inflammation and correlate with increased survival rates, reduced risk of
death, and reduced risk of MIs that lead to death especially amongst those with high
inflammatory processes (Crismaru & Diaconu, 2015). Also, it was noted that there was
improvement in endothelial dysfunction and reduced nitric oxide levels in association with
dyslipidemia that leads to increased blood flow in areas of microcirculation (Crismaru &
Diaconu, 2015).
Diet Counseling to Reduce the Risk of PAD
Diet counseling for patients with diabetes that have PAD is centered around glycemic
control and a HbA1C goal of <7.0. The diabetes plate method is an easy way to put together
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healthy meals that assists patients in the management of blood sugar (American Diabetes
Association, 2020). This method creates optimally portioned meals that balances vegetables,
protein, and carbohydrates without the need to weight or properly measure food (American
Diabetes Association, 2020). All that is needed is a 9-inch plate as the standard plate size to
determine appropriate portion sizes. Half of the plate is filled with non-starchy vegetables as they
do not raise blood sugar levels as much as other types of food. The non-starchy vegetables
provide vitamins, minerals, and fiber in the diet. Examples of these types of food include
asparagus, broccoli, cauliflower, brussels sprouts, cabbage, carrots, celery, cucumbers, eggplant,
mushrooms, okra, green beans, peppers, salad greens, squash, and tomatoes. One quarter of the
plate is filled with lean protein foods such as fish, chicken, lean beef, soy products, and cheese.
Lean proteins are low in fat making these food types a healthier choice versus proteins from
animal sources that contain saturated fats which increase heart disease risk. Examples include
chicken, turkey, eggs, fish, shellfish, lean beef (chuck, round, sirloin, flank, or tenderloin), lean
pork (center loin chop or tenderloin), lean deli meats, cheese, and cottage cheese. The last
quarter of the plate is filled with carbohydrate foods that includes grains, starchy vegetables,
beans, legumes, fruit, yogurt, and milk. These types of food effect blood glucose the most.
Examples of carbohydrate foods include whole grains such as brown rice, polenta, oats/oatmeal,
quinoa, bread, pasta, tortillas, acorn squash, butternut squash, green peas, plantain, potato,
pumpkin, sweet potato, beans, legumes, fruit, and dairy products. The final component of the
meal is water or a low-calorie drink. Low calorie drink options include unsweetened tea,
unsweetened coffee, sparkling water/club soda, flavored water, diet soda, or other diet drinks
(American Diabetes Association, 2020).
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Exercise Counseling to Reduce the Risk of PAD
The majority of patients with PAD struggle with impaired walking endurance, increasing
functional decline, and physical disability (McDermott et al., 2021). Those patients with PAD
and DM struggle even more. This is due to the decrease in oxygen supply to the lower
extremities that leads to ischemia causing individuals to experience varying degrees of pain,
tightness, and weakness. Overtime this contributes to worsening dysfunction and ultimately
mobility loss (McDermott et al., 2021). Goals for these patients are centered on improving
walking performance and preventing further functional decline. Activities that focus on
behavioral changes whether supervised or at home are recommended as they have been shown to
improve walking endurance for these patients (McDermott et al., 2021). One study revealed that
patients with diabetes walked significantly shorter distances, at a slower pace, and with shorter
performance scores (McDermott et al., 2021). Diabetes severity was found to have a direct
correlation to a patient’s functional abilities (McDermott et al., 2021). The ADA (2020)
recommends that patients with diabetes should perform aerobic and resistance exercises on a
regular basis. Aerobic activities should last a minimum of 10 min with an overall goal of 30 min
a day or more if the patient is able (American Diabetes Association, 2020). Exercise intensity
should gradually increase in both frequency and duration. The goal should be to reach 150 min a
week at a moderate intensity (American Diabetes Association, 2020). The avoidance of a
prolonged sedentary lifestyle can help control a person’s glucose levels and many times prevent
type 2 diabetes. Older adults have been shown to benefit from exercises that focus on improving
range of motion, strength, and balance (American Diabetes Association, 2020).
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Smoking Cessation to Reduce the Risk of PAD
Smoking is a key modifiable risk factor for all manifestations of cardiovascular disease
including PAD (Ratchford & Khoury, 2020). Smoking cessation counseling is an important first
step in the treatment of PAD as it is known to improve symptoms of claudication. Knowledge is
key and plays a part in motivating patients to quit smoking. This is what this project strived to
achieve as it has been noted that up to 80% of patients with PAD are current or former smokers
(Ratchford & Khoury, 2020). Smoking should be addressed using evidenced-based
pharmacologic treatment and behavioral therapy as needed (Ratchford & Khoury, 2020). The
patient-centered outcomes related to treatment practices in peripheral artery disease
(PORTRAIT) study enrolled 1,272 patients with PAD at 16 vascular specialty clinics (Patel et
al., 2018). Active smokers made up 474 of the patients. Of the remaining patients, 660 were
former smokers, and 138 were never smoked. This study revealed that most patients were likely
to quit early in the treatment process and quickly relapsed. At 12 months, 72% of all patients still
smoked. The predominant strategy used to help these patients quit smoking was to tell patients to
stop. Less than 1 in 5 smokers were referred to a smoking cessation program and only 1 in 10
received pharmacological treatment (Patel et al., 2018). Smoking patterns were dynamic over
time, with a high rate of relapse which reinforced the need for repeated and consistent support
and intervention. These interventions were not addressed in this project specifically due to time
and resource restraints but are recommended for future projects. A study in patients with diabetes
revealed a cessation rate of 11.1% amongst those who underwent intensive smoking cessation
programs within 6 months (Campagna et al.,2019). The prevalence of smoking among patients
with diabetes in combination with poor glycemic control and the low success rates of patients
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stopping smoking on their own supports the importance of counseling smokers with diabetes of
the risks associated with smoking (Campagna et al.,2019).
Summary of the Evidence
The burden of PAD is a global health issue that has been associated with loss of life and
limb that is expected to increase with the aging population. Guidelines have been outlined by the
AHA and ACC to guide healthcare providers in the treatment of individuals at high risk of
developing PAD and those with a known diagnosis of PAD (Virani et al., 2020). The use of
pharmacotherapy is focused on the reduction of cardiovascular ischemia and limb-related events.
Evidence varies amongst studies and professional organizations leaving healthcare providers to
decide amongst themselves what therapies are best for their patients. There is limited research
related to the long-term management of PAD. Current clinical practice guidelines rely heavily on
related evidence and consensus of experts in the field. Further research is needed to determine
what therapies will have a significant impact on improving morbidity and mortality rates in
patients with diabetes that have PAD. Diet, exercise, and smoking cessation education are also
key components to help reduce the risk of patients with diabetes from developing PAD or
worsening of PAD as these factors can be modified. Primary care providers should strive to
provide their patients with care that is comprehensive, and protocol driven.
Methods
Project Framework
The Plan-Do-Study-Act (PDSA) cycle was used to develop this quality improvement
project. This framework is useful in the adaption of evidence-based interventions into day-to-day
operations (Coury et al., 2017). The topic that was chosen for this project was chosen after a
detailed needs assessment was conducted and revealed a gap in screening diabetics for PAD risk
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and properly testing those patients that were identified to be at high risk. The clinic had the
capabilities to screen and test these patients but had no formal processes in place prior to
implementation of the project’s planning state (Plan). A screening tool, diagnostic testing
process, and intervention plan was created in collaboration with the clinic’s MAs and provider.
Once the plan was finalized the staff and provider were educated on the process and the project
was implemented over a 10-week period (Do). During the implementation period, I performed
weekly audits to monitor compliance and adherence to the project plan. The clinic’s provider
was updated regularly on the project’s progress (Study) to assist in identifying any areas that
needed to be adjusted or addressed. Potential barriers were identified before the project was
implemented to include the prominent use of telemedicine over traditional office visits during the
COVID-19 pandemic. This was done by creating two separate processes the clinic staff could
follow based on the type of visit the patient had to ensure all patients had the opportunity to
benefit from the project plan regardless of the visit type (Act). Even though these barriers were
anticipated, it remained a challenge in meeting the expected outcomes of the project. The PDSA
cycle helped uncover implementation barriers that needed to be addressed in order to ensure that
this project was sustainable for the clinic over time. Recommendations were made at the
completion of the 10-week implementation period to ensure future success.
Project Interventions
During a patient’s regularly scheduled office visit, the MAs initiated the screening tool
for any patient that had a diagnosis of DM. The screening tool can be found in appendix C. The
information gathered from the screening tool included patients’: (a) age, (b) gender, (c) smoking
history, (d) hypercholesterolemia history, (e) hypertension history, (f) heart disease history, (g)
MI history; (h) stroke history, (i) and obesity status. These health history findings helped to
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identify patients at increased risk of developing PAD. The screening tool also asked about family
history related to PAD, heart disease, MI, and stroke since a positive family history of any of
these specific risk factors increases the risk of patients developing these diseases and
subsequently PAD. The screening tool was written in English using layman terms at a 6th grade
reading level. Along with the screening tool, patients received an education sheet outlining the
definition of PAD and its risk factors. The education was available in English and Spanish. If a
patient indicated any positive history related to the risk factors on the screening tool, this
triggered the MAs to conduct a digital ABI test.
A care plan was placed on the backside of the screening tool. The MAs were responsible
for documenting the date of the most recent HbA1C results, lipid panel results, comprehensive
metabolic panel (CMP) results, and current blood pressure reading for patients’ who were
screened. This helped to ensure that a lipid panel and CMP had been drawn within the past 6
months and that a HbA1C had been drawn within the past year. This information assisted the
physician in evaluating patients’ DM status, risks for complications that could result in PAD, and
helped ensure that an appropriate treatment plan was implemented.
Once it was determined that a digital ABI test should be performed on a patient, the MAs
provided the patient with verbal information regarding the benefits and risks of having an ABI
test performed and how diabetes plays a factor in increasing their risk for PAD. The patient was
informed that the ABI testing would be billed to their insurance. However, if the patient’s
insurance did not cover the ABI testing, then the ABI testing was provided to the patient at no
cost. It is interesting to note that the owner of the clinic had decided that ABI testing was
essential in helping to diagnosis patients at risk for PAD and therefore any ABI testing that was
not covered by insurance would be provided gratis. The patient was also provided an explanation
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of the risks associated with declining any of the diagnostic testing. This was necessary for
patients to make an informed decision. If the patient was having a telemedicine visit, then an
appointment was made for the patient to come in to get the ABI done. If the patient was being
seen in the office, then the ABI was done at that time given that it did not take very long to
complete.
After the digital ABI test was completed, the results were documented in the EMR,
noting if the results were normal or abnormal. Additionally, the results were added to the
physician’s note so he could review the results as he was seeing the patient to discuss the
findings and offer a recommended treatment plan. Any patient that had an ABI result >1.4 or
<0.8 was referred to a vascular specialist by the physician.
Laboratory studies were ordered by the physician after reviewing the information
obtained from the care plan. Patients with DM that were diagnosed with hypertension or who had
an elevated blood pressure >130/80 mmHg were evaluated for the need to add an
antihypertensive medication or to adjust the dosage of their current antihypertensive medications
if already prescribed. All patients with DM who identified at least one more risk factor listed on
the screening tool were prescribed a low to moderate dose of atorvastatin unless a higher dose
was indicated according to the USPTF’s (2017) clinical practice guidelines for cardiovascular
care including PAD. Similarly, all patients with DM who identified at least one more risk factor
listed on the screen tool who were identified as being at high risk for PAD were placed on
antiplatelet aggregation therapy such as aspirin, apixaban, or rivaroxaban by the provider as a
preventive measure if the patient was not already on an antiplatelet aggregation therapy.
All patients with DM who identified at least one more risk factor listed on the screening
tool were provided diet counseling during the office visit. This dietary counseling included a
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handout provided by the ADA that was given to the patient to take home to review and reference
as needed. The handout had a graphic of a plate of food properly divided into food groups with
healthy option examples. The graphic also compared portion sizes to a patient’s fist size so
patients could easily measure their food without having to weigh the food or use a measuring
cup. All patients with DM who identified at least one more risk factor listed on the screening tool
were provided exercise counseling during their office visit. This exercise counseling included a
handout provided by the ADA that addressed setting achievable goals, how to start and
incorporate exercise, and how to gradually increase exercise. Any patient with DM that currently
smoked was provided smoking cessation counseling during their office visit. This smoking
cessation counseling included a handout provided by the ADA discussing why it is important to
quit and how to do so with the help of your healthcare provider.
As previously mentioned, a care plan was included on the reverse side of the screening
tool outlining all the preventative measures and risk factor management therapies that were to be
used to reduce the risk of PAD in patients with DM. The MAs and/or physician placed a
checkmark next to the interventions that were completed during the patient’s current office visit.
This helped the physician and clinic staff keep track of which treatment therapies were
implemented for each patient. If a patient had a contraindication for implementing an
intervention such as an allergy to a medication or if the patient refused an intervention, the MAs
and/or physician documented this on the care plan. Additionally, the physician documented the
completed interventions in his progress note to ensure compliance with documentation
requirements and to assist in appropriate billing for the patients. The MAs documented the ABI
result in the patient’s chart where it could easily be found in the notes section including the date
that the ABI was completed. The clinic had planned to add the ABI to a spreadsheet within one
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of the available patient tabs but was unable to do so before the project implementation. At the
end of each day, the screening forms and care plans were collected and placed in a folder at the
nurse's station in a locked drawer. Only the clinic staff, physician, and I were able to access the
locked drawer. These documents provided the clinic with the ability to track PAD screenings and
interventions that were implemented for each patient but also helped with data collection for the
purposes of this project. The clinic utilized both a paper and electronic charting system. A paper
chart was created for each patient during each visit and included a medication list and problem
list along with a progress note and any other documents utilized during the visit. The physician
utilized this paper chart while talking with the patient as it provided him with easy access to their
medical information. At the end of this visit, the information on the paper chart was then
transferred to the electronic chart by the physician and MA. At the end of each month, the charts
were filed in the clinic’s locked filing cabinet and referenced if necessary. Because the clinic
utilized paper charts during their day-to-day operations, the choice was made to make the
project’s documents on paper versus creating the documents electronically.
Progress in completing screenings, completion of ABI testing, implementation of
preventative measures, and referrals to vascular specialists were evaluated weekly using data
collected from the care plan to determine progress in meeting the project’s outcomes and helped
me to identify any issues in data collection. I provided the staff and the provider with compliance
information with the project interventions each week to ensure success in implementation of the
project interventions.
Potential Barriers
Potential barriers included the COVID-19 pandemic that impacted the ability to see all
patients face to face since appropriate safety measures had to be maintained. This meant that
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some of the visits were conducted via telemedicine. I anticipated this early on prior to the
project’s implementation and created a process whereby all interventions could be completed
regardless of the patient having a telemedicine or a face-to-face visit. I created a process
flowchart for the staff to reference as needed and posted it throughout the clinic in all the
common areas for the staff.
Scheduling of last-minute appointments and rushed preparation of patient charts were a
barrier to implementing this project as well. Many times, patients were squeezed into the
schedule without adequate time allotted for the office visit. This also resulted in chart preparation
being done quickly by the MA’s depending on the amount of time they had from the time of the
patient’s call to the time of the patient’s appointment. This was in addition to the MAs’ workload
that was already assigned. I ensured that the screening forms and care plans were easily
accessible to the MA’s and that each packet was pre-made to ensure no extra time was needed to
avoid taking away from the MA’s daily duties.
The lack of health insurance coverage by some patients was potentially a barrier in
completing the ABI testing. However, the physician agreed to provide the ABI testing gratis if
the patient had no insurance or if the patient’s insurance did not cover the ABI testing.
At the beginning of the project’s implementation the MA’s and provider were engaged
and followed the process. At that time, all patients were being seen through telemedicine, but the
provider agreed to allow patients to come into the office once a week to get the ABI testing done.
Scheduling patients to come in for ABI testing was difficult as many patients preferred to stay
home and were not open to coming into the office because of their age and the high risk for
complications if they contracted COVID-19. The COVID-19 vaccine was available at the time
but was difficult to obtain and was only available to select individuals. Many patients were still
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hesitant to get the vaccine until more information was disseminated to the public regarding
potential side effects. One week into my project’s implementation, the city was impacted by a
winter storm that left most of the State of Texas without water or electricity for several days
along with the streets condition being dangerous that required the clinic to close for the entire
week to ensure the safety of their staff and patients. The clinic was also without electricity or
water during this time. The following week the clinic’s computer servers went down which
presented another barrier as the staff were digging through old paper charts for patient
information to use for each patient’s visit. Unfortunately, many appointments had to be
rescheduled. Once the computer servers were up and running, the staff picked up where they left
off with the project. After a few weeks went by, I noticed that the staff were utilizing the process
less and less. I brought this to the provider’s attention, and he said he would talk to the staff.
Another week and a half went by, and I still was not seeing the staff following the process and I
met with the provider again to address my concerns and provided him with preliminary data
from the project. He stated that the staff had their hands full with wellness examinations as the
clinic had begun seeing patient’s face-to-face more regularly and this was their current priority as
several of these patients were overdue for examinations due to the pandemic. He then stated that
he believed that the number of ABI tests that had been done up to this point in the project’s
implementation was significant for a clinic of their size. This barrier impacted the project
immensely and impeded its further progress despite my efforts to encourage compliance during
the implementation phase.
Ethical Considerations
It is important to keep in mind that patients who lack health insurance coverage might be
unable to afford the recommended PAD screenings and preventative treatments for their chronic
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illness(es). The provider needed to discuss what screenings and interventions would fit within
uninsured patients’ budgets and would still provide an acceptable level of care to address
patients’ needs. Many insurance companies also do not cover ABI testing which could delay
properly diagnosing patients. If insurance companies do not cover certain diagnostics and
interventions, many providers may decide against implementing these services for their patients.
This could lead to not diagnosing a patient with PAD until he/she was symptomatic and needed
to be referred to a specialist.
All patients have the right to refuse ABI testing or any of the risk reduction strategies that
were offered to them. However, it is also the provider’s responsibility to explain all the risks and
benefits of these diagnostics and interventions to ensure that the patient made an informed
decision about how to manage their own health.
While the clinic abided by all the Centers for Disease Control and Prevention
recommendations regarding COVID-19, there was still a risk to the staff and patients when
scheduling ABI testing appointments since this required face-to-face meetings. The provider was
confident in the clinic’s disease prevention methods and was willing to allow patients into the
office to have the ABI testing done. Not all the patients who needed ABI testing were willing to
assume this risk and preferred to postpone the ABI testing until they received their COVID-19
vaccinations and felt safe again. Patients were encouraged to schedule the ABI testing as soon as
they feel comfortable coming to the clinic.
The University of the Incarnate Word Institutional Review Board reviewed this DNP
Quality Improvement Project and deemed it as non-research. Patient data collected for the
project was secured at the DNP project site with all other clinic patient information. I completed
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all required Health Insurance Portability and Accountability Act (HIPAA) training before the
start of the DNP project.
Results
Demographics
A total of 899 patients were seen during the 10-week project implementation period from
February 8, 2021 to April 16, 2021. Of these 899 patients, 308 (34%) had DM. Males made up
59% of the population that had DM. A total of 295 (96%) of the patients with DM were screened
for PAD risks with 257 (87%) patients meeting the high-risk criteria that triggered the need for
ABI testing. This exceeded the first outcome goal for this project which was to increase the
number of patients with DM screened for risk factors of PAD from 0% to 70% within 10 weeks.
Of the 295 patients screened, 46 (16%) had their ethnicity documented in the EMR.
Results indicated that 76% were Hispanic, 20% were White, 2% were African American, and 2%
fell into the other category. As previously stated, the clinic did not consistently document patient
ethnicity in the EMR. The new patient packet included an area for ethnicity to be documented
but if the patient left this section blank, then it was not transferred into the EMR. Table 4
provides a summary of patient demographics identified during the initial screening process.
Recommendations for future revisions to this process include requiring the clinic staff to
ask patients their ethnicity during the time of the patients’ visits and updating that information in
the EMR. This will assist in identifying potential trends related to demographic data that can
assist in addressing any potential barriers that may impede patients with diabetes from receiving
the care that is recommended by the clinical practice guidelines to improve their overall
outcomes and quality of life.
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Table 4
Patient Demographics From Project Implementation
Characteristics

Percentage

Age Group
30-39 years

2%

40-49 years

9.8%

50-59 years

21%

60-69 years

32.5%

70-79 years

23.7%

80-89 years

10%

90-99 years

0.5%

Gender
Male

59%

Female

41%

Ethnicity
Hispanic

76%

Black

2%

White

20%

Other

2%

Screening
Table 5 provides a summary of patient risk factors related to health history that were
identified during the initial screening process. Hypertension, hyperlipidemia, and obesity were
the most common risk factors identified in the patients with diabetes that presented to the clinic.

PERIPHERAL ARTERY DISEASE DETECTION & MANAGEMENT

44

Table 5
Patient Risk Factors Identified During the Project Implementation
Characteristics

Percentage

Risk Factors
Hypertension

72%

Hyperlipidemia

68%

Heart Disease

22%

Stroke

3%

Obesity

51%

Smoker

5%

Family History
PAD

0.7%

Heart Disease

2%

Stroke

0.7%

Due to the COVID-19 pandemic, a majority of patients fell behind on their regularly
scheduled laboratory tests including their HgA1C, lipid panel, and comprehensive metabolic
panel (CMP). These tests are preformed regularly to monitor each patient’s state of health in
relationship to their diagnosis of DM and their response to their current treatment regimen. This
is important as it determines a patient’s individualized plan of care, which aims to ensure their
health needs are being met. This can include the addition or removal of selected pharmacological
therapies that assist in management of the patient’s DM and PAD. Of the 295 total patients seen
during the implementation period, 5% had a lipid panel within the last 6 months, 10% had a
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CMP in the last 6 months, and 10% had a HgA1C in the last 6 months. The average HgA1C was
8.4 which is well above the goal of <7.0 set by the ADA.
Overall, 295 (96%) of the patients with DM were screened for PAD risks with 257 (87%)
patients meeting the high-risk criteria that triggered the need for ABI testing. This exceeded the
first outcome goal for this project which was to increase the number of patients with DM
screened for risk factors of PAD from 0% to 70% within 10 weeks.
ABI Testing
Only 23 (9%) of the patients who met the criteria for ABI testing had the ABI testing
performed. Out of these 23 patients, 3 (13%) had abnormal ABI test results which revealed one
patient with mild PAD (0.6-0.89), one patient with moderate PAD (0.3-0.59), and one patient
with severe PAD (0-0.29). This fell short of the second outcome for this project which was to
increase the utilization of ABI testing for patients with DM that have a risk factor for PAD from
0% to 50% in 10 weeks. As previously mentioned in the ethical section of this paper, barriers
that impeded on the achievement of the project’s desired outcomes included the lack of
participation and engagement from the clinic’s staff, patient fears related to the COVID-19
pandemic, and the winter storm closing the clinic for a week and temporarily shutting down the
clinic computer server.
Antiplatelet Therapy
Antiplatelet therapy was utilized by 66% of the patients who presented to the clinic with
a diagnosis of diabetes. Of these, 17% of patients were prescribed the therapy after seeing the
provider. This fell short of the fourth outcome to increase the utilization of antiplatelet therapy in
patients with DM at an increased risk of developing PAD from 49% to 75% in 10 weeks. An
allergy to an antiplatelet was documented in nine of the patients seen. Many were prescribed the
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medication by the provider at a previous visit but chose not to take the medication. This was
observed during the chart audits as the MAs performed medication reconciliation for each patient
during their office visit. The MAs noted when patients were not taking the prescribed
medications or if the patients had stopped taking the prescribed medications. Further
investigation into why the patients chose not to take the medication is recommended to better
understand this barrier in adherence to guideline recommendation.
Statin Therapy
Statin therapy was utilized by 87% of patients with diabetes. This fell short by 3% from
meeting the third outcome to increase the utilization of statin therapy in patients with DM at an
increased risk of developing PAD from 73% to 90% in 10 weeks. A statin allergy was noted in
13 of the patients with two patients who refused statin therapy despite having received education
by the provider on its benefits. Further investigation into contributing factors associated with
patient refusal is recommended to better understand barriers attributing to the lack of adherence
to guideline recommendations is recommended. All patients have the right to refuse therapies
recommended by their healthcare provider, but it is the provider’s ethical responsibility to ensure
that the patient has the necessary information to make an informed decision.
Diet and Exercise Counseling
Diet and exercise counseling was provided to 43% of the patient population. This fell
short of the fifth outcome to increase diet and exercise counseling amongst patients with DM at
an increased risk of developing PAD from 0% to 75% in 10 weeks. Most of the office visits were
via telemedicine. Therefore, diet and exercise counseling was provided to most of these patients
remotely as since they did not come into the office for the ABI testing. Telemedicine continued
to be the clinic’s primary method of patient care delivery during the project’s implementation
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period due to the COVID-19 pandemic, accounting for 75% of all visits. Because the education
was provided primarily via telemedicine, the majority of patients did not get to receive the
education handouts that were available in English and Spanish unless the patients came to the
clinic to have an ABI preformed.
Smoking Cessation
Of the total population seen, 14 patients were active smokers and all of them received the
smoking cessation education outlined for this project. This met the seventh outcome of
increasing the provision of smoking cessation education to patients who have diabetes and are
active smokers from 0% to 100% in 10 weeks. As previously outlined in the methods section,
this education focused on informing the patients about the role smoking plays in increasing their
risk of developing PAD and encouraging them to stop. Methods to assist in smoking cessation
were discussed with the patients by the provider on a case-by-case basis.
Referral to Vascular Specialist
Out of these 23 patients, 3 (13%) had abnormal ABI test results that required referral to a
vascular specialist. All 3 (100%) of these patients were referred to a vascular specialist within a 2
week period, which met the seventh outcome for this project that sought to increase the referral
of patients with DM that have an abnormal ABI > 1.4 or <0.8 to a vascular specialist from 0% to
100% within 2 weeks of testing. The findings and recommended treatment plan for these three
patients should be forwarded from the vascular specialist back to the provider in this clinic
before these patients have their next scheduled office visit at the clinic.
Summary of Results
COVID-19 greatly affected the normal procedures for the clinic. The vast majority of the
office visits were via telemedicine which required patients to schedule another in-person office
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visit to complete the ABI testing. At the time that the project was implemented, the COVID-19
vaccine was not readily available to the general population. Many patients were limiting any
face-to-face contact with others in order to limit their exposure to COVID-19. Additionally,
Texas experienced one of the worst snowstorms in its history resulting in a Statewide power
outage that effected clinic operations and the EMR system. This resulted in the clinic having to
shut down for 1 week. Both events most likely contributed to not meeting the ABI testing goal.
The inability to provide patients with educational materials at the time of the office visit and the
limited amount of time the provider had to see patients most likely accounts for not meeting the
diet and exercise counseling goals. Some progress was made in ensuring that patients with
diabetes who were at risk for PAD were prescribed an antiplatelet medication and a statin as a
risk reduction strategy in accordance with the clinical practice guidelines. The clinic will most
likely reach the anticipated adherence goals as these interventions are cemented into the clinic’s
routine. The rest of the anticipated adherence goals were achieved. Table 6 provides a summary
of the results obtained from this project.
Discussion
When the project’s process (Appendix E) was followed by all staff members and the
provider, the project implementation ran smoothly. The vast majority of the patients were
receptive to the interventions and the education provided. Many of the patients verbalized their
unfamiliarity with PAD and were surprised to learn that they were at risk for PAD based on their
medical diagnoses and history. This most likely helped to motivated them to learn more about
how to improve their lifestyles through diet and exercise and reduce their PAD risk. The
importance of both antiplatelet and aspirin utilization was also discussed at length with these
patients. Many verbalized their understanding regarding the important role these medications
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Table 6
Outcome Summary Pre-Intervention and Post-Intervention
Intervention

Pre-Intervention

Anticipated

Post-Intervention

Outcome
Staff education

0%

100%

100%

Screening form

0%

80%

96%

ABI testing

0%

50%

9%

Statin utilization

73%

90%

87%

Antiplatelet utilization

49%

75%

66%

Diet/exercise counseling

0%

80%

43%

Smoking cessation education

0%

100%

100%

Vascular referral

0%

100%

100%

played in their daily regimen while others believed these medications to be just another pill in
their pillbox. Once the ABI was completed and the results were reviewed, some patients
verbalized surprise about ease of ABI testing and the short amount of time it took to complete
the ABI testing.
Difficulties with project implementation compliance arose when the staff were no longer
following the project process flowchart (Appendix E) around week 5. The MAs were only
completing the screening tool but were not following through with the rest of the project
interventions. Once I identified that this was occurring, I notified the provider to discuss what
could be done to get the staff back on track in implementing the project plan. The provider
reinforced the importance of completing the interventions with the staff as they were essential in
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helping to complete the care plan that had a direct effect on patients’ long-term outcomes and
helped direct the provider on the interventions that needed to be included in the patients’ plans of
care. Despite reinforcement by the provider, the staff continued to show a lack of participation.
I once again brought this to the attention of the provider. However, this time the
provider’s response was unexpected. Previously, he had expressed his full support of the project
and assisted with its creation prior to implementation. Now in week 6 of implementation, the
provider stated that he believed that the number of ABI’s that had been completed was sufficient
for the size of the clinic and stressed that the clinics current focus would revolve around the
completion of patient wellness examinations which had been significantly delayed due to the
COVID-19 pandemic. At this point, it was evident that the project would not meet all the
expected outcomes as the provider was the driving force in directing operations of the clinic.
Without his support, not much more could be done. Wellness visits are essential as they provide
healthcare providers with an update on patients’ overall health. The goals of this project were
aimed at identifying those at risk of developing PAD which is consistent with the purpose of
having wellness examinations done on an annual basis. I recommended that the PAD screenings
be integrated as a component of the wellness examinations to increase future compliance with
screenings and reduce the risk of life and limb events for patients with diabetes. The earlier PAD
is identified, the sooner referrals can be made, intervention can be initiated, and long-term health
outcomes can improve.
The strength of this project’s design was that all potential variables were considered
during the development of the project process flowchart (Appendix E) to include both
telemedicine and face-to-face visits. The project process flowchart provided the staff and
provider an easy-to-follow approach to ensure the project’s success. All patient packets were pre-
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assembled to ease the burden on the MAs. The packets were easily accessible to the MAs at the
nurse’s station. While the project added a small amount of workload on to the MA’s current
workload, it was not observed to have taken away from their regular duties as I noticed that the
MAs continued to have time to check their social media, take personal photographs, and make
personal calls. This information was relayed to the provider during our second meeting in which
we discussed process flow issues.
Relationship to the Evidence
The results of the project were consistent with evidence emphasizing the underutilization
of prevention and lifestyle counseling in patients with PAD. Berger and Ladapo (2017) identified
that prevention and lifestyle counseling is underutilized in patients with PAD. This is
concerning, since most of the patients seen during this project’s implementation also had
diabetes mellitus, which increases their severity risk of developing PAD. Likewise, this project
supported the findings of Aday and Everett (2018) who identified that the use of statin therapy is
underutilized in patients with PAD. As previously stated, patients seen during this project’s
implementation also had diabetes mellitus. This comorbidity not only increased the likelihood
that these patients would develop PAD but also increased the likelihood that these patients would
develop an underlying cardiac condition such as atherosclerosis and hypertension placing them at
greater risk for a MI. This project identified that prescribing of statins and antiplatelet therapy
such as aspirin was not a consistent part of the practice. Based on findings from their study,
Gerhard-Herman et al. (2016) identified that despite limited evidence, aspirin therapy may
reduce the risk of complications associated with PAD and statin therapy improved both
cardiovascular and limb outcomes in patients with PAD. These findings support a continued
efforts for the primary care practice to follow the project process flowchart (Appendix E) that
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incorporates the use of antiplatelet and statin therapy. While all patients seen during the project
implementation who smoked were provided smoking cessation counseling, it would be prudent
to encourage patients to enroll in some type of smoking cessation program. Patel et al. (2018),
identified that simply telling patients to stop smoking did not result in long term cessation of
smoking. Referral to a more structure smoking cessation program that includes both behavioral
and pharmacological treatment may increase the likelihood of success. Overall, this project
improved the process of caring for patients with diabetes who were at risk for developing PAD.
The project process flowchart addresses the main risk factors associated with PAD and includes
pharmacological and lifestyle management therapies based on the most current evidence. The
challenge is incorporating current clinical practice guidelines into the day-to-day practice despite
the current challenges associated with the COVID-19 pandemic. Utilization of the project
process flowchart will help to improve the quality of care for these high-risk patients at the
primary care level.
The greatest limitation in the implementation of this project was the amount of ABI’s
conducted, which were much less than what was anticipated for this project making it impossible
to determine the number of patients both symptomatic and asymptomatic who had PAD but were
unaware of their diagnosis. Without an ABI, no formal diagnosis of PAD can be made. The low
number of ABI’s that were performed was due to the barriers previous described such as
telemedicine office visits, inconsistent use of the project process flowchart, and the COVID-19
pandemic. These barriers were not identified in previous studies. These are areas that need
further investigation to determine what strategies can be used to improve compliance in ABI
testing. It is likely that if the barriers had not been present, the testing numbers might have
improved significantly. Of the 257 high risk patients identified, 23 (9%) had the ABI testing
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performed. Out of these 23 patients, 3 (13%) had abnormal ABI test results. This is in contrast to
Tóth-Vajna et al. (2019) who found that 23% of their patient population to have abnormal
results. The low number of actual ABI test performed during this project’s implementation limits
the ability to compare outcomes with those found by Tóth-Vajna et al. (2019). Once consistent
implementation of the project process flowchart occurs in this primary care setting, a comparison
between patient outcomes for this practice and the literature can more reliably be established.
As previously mentioned, the patients with diabetes seen in this clinic often had
hypertension (72%), hyperlipidemia (68%), and obesity (51%). This is not an uncommon
finding. Tóth-Vajna et al. (2019) noted that the health professionals’ follow-up study had similar
findings that included the identification of hypertension (77%), hyperlipidemia (55%), diabetes
(33%), and active smokers (24%) as frequent vascular risk factors.
Active smokers made up 5% of the patients with diabetes in this practice that were found
to be at high risk of developing PAD. This was significantly less than the 24% found by TóthVajna et al. (2019). Tóth-Vajna et al. (2019) identified that major amputations in Hungary were
triple the international average due to the late recognition of PAD. Observational studies found
amputations, myocardial infarctions, and death risk to be significantly greater among those who
continue to smoke with a known diagnosis of PAD in comparison to those who stopped smoking
(Virani et al.,2020). The added comorbidity of DM increases the risk that patients seen in this
practice who smoke will develop PAD or an associated limb event.
Project results revealed 68% of patients to have hyperlipidemia while an observational
study conducted in several general practice offices revealed 55% of the population to have
hyperlipidemia (Toth-Vajna et al., 2019). This may be attributed to a higher incidence of
uncontrolled DM in this area. Statin therapy is known to stabilize and regress atherosclerotic
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plaques, but statin therapy has also been found to reduce inflammation and correlates with
increased survival rates and reduced risk of death (Crismaru & Diaconu, 2015). It has also been
noted to improve endothelial dysfunction and reduced nitric oxide levels in association with
hyperlipidemia that leads to increased blood flow in areas of microcirculation (Crismaru &
Diaconu, 2015). Statins were utilized by 87% of high-risk patients in this project postimplementation compared to the 73% pre-implementation. This was more than the 62.2% that
was found to be taking a statin in the REACH registry (Parvar et al.,2018).
While there is no way to reduce the risk of PAD associated with advanced age, there are
medical therapies and lifestyle counseling methods that can reduce the incidence of PAD and
cardiovascular events associated with PAD due to modifiable risk factors. Risk factors such as
smoking, hypertension, hypercholesterolemia, and DM significantly increase PAD risk
particularly when more than one modifiable risk factor is present (Newman et al., 2017).
Smoking increases PAD occurrence by 2-6 times and further increases based on the number of
cigarettes smoked daily and the number of years the individual has smoked (Tóth-Vajna et al.,
2019). Patients with diabetes have 2.4 times greater risk of developing PAD and critical limb
ischemia than those individuals without diabetes (Tóth-Vajna et al., 2019). Amputation is five
times higher for patients who have developed PAD (Tóth-Vajna et al., 2019). Further evaluation
over time is needed to draw specific conclusions about this project’s effect on long term patient
outcomes.
Limitations
There were several limitations to implementation of this project. One of the biggest
obstacles centered around the primary use of telemedicine instead of face-to-face office visits
and the lack of opportunities to obtain ABI testing while patients were being seen by the
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provider. This resulted in patients needing to schedule multiple visits with the physician to obtain
the ABI testing and to ensure that all the interventions were addressed. This caused confusion for
some patients and resulted delays in diagnosing PAD in patients identified to be at high risk and
missed opportunities to implement preventative PAD interventions.
The EMR was also a limitation as the current EMR system was not able to extract
reliable data reports and lacked the capability to add the project’s interventions into a spreadsheet
that could be tracked over time. This resulted in staff having to locate project outcome data in
patients’ paper charts and increased the likelihood of paper documents being lost. A more
advanced EMR system would allow for provider alerts and intervention reminders which would
prompt staff to complete the interventions and allow for real time data collection instead of
manual data collection which was a time consuming and tedious task. However, new EMR
systems can be expensive and thus cost prohibitive for the clinic.
Unexpected barriers to implementing this project included the power outages that
occurred during a winter storm that effected the Texas statewide electrical grid resulting in the
closure of the clinic for a week and computer server disturbances. This was compounded by the
COVID-19 pandemic that resulted in patients being hesitant to come into the office to obtain
their ABI’s due to a fear of contracting the COVID-19 virus if they left their homes. During
implementation of this project the COVID-19 vaccine had just become available to selected preidentified patient groups based on age, health issues, and profession type. Many patients were
also hesitant to receive the vaccine as it was still very new and was not fully FDA approved.
These barriers were out of the anyone’s control. These barriers directly impacted the project’s
implementation and subsequent results. Without these specific barriers the project might have
been able to be more fully implemented.
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Recommendations
Project recommendations include the screening of patients with diabetes for PAD risk at
face-to-face office visits to ensure the completion of ABI testing. The telemedicine process will
work if staff follow the project process flowchart and patients make ABI testing appointments
with the receptionist before concluding their telemedicine visit. Any deviations from the project
process flowchart increase the likelihood of a process breakdown resulting in missed
opportunities to identify, test, and diagnose patients at risk of developing or having PAD and
implementing appropriate interventions to reduce the risk of complications associated with PAD.
The staff should be closely monitored for compliance in following the project process flowchart
and be held accountable if it is found that they are not following the flowchart. Compliance with
the project process flowchart should be rewarded since staff recognition can ensure continued
compliance both those staff members that have been recognized and encourage the other staff
members to improve their performance. The movement of PAD screenings to the annual
wellness visit would assist in ensuring that ABIs are routinely conducted for patients at risk for
PAD. Various other screenings are performed during these wellness visits which makes this the
prime time to implement PAD screening and ABI testing. This will help ensure compliance with
the project process flowchart and reinforces the reason for the wellness visit which is primarily
prevention focused. Further investigation into the reasons why patients refused antiplatelet and
statin therapy is also recommended to better understand the barriers to the adherence of these
specific guideline recommendations.
Primary care providers, insurers, and other members of the healthcare team need to do a
better job of educating both patients and their fellow colleagues on the importance of prevention
and pharmacotherapy to reduce the effects of PAD on both life and limb of patients with diabetes
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and PAD. A combination of guideline recommended therapies to include cardiovascular
preventative medications such as antiplatelets and statins along with secondary prevention and
lifestyle counseling (diet/exercise counseling and smoking cessation) have proven time and time
to improve quality of life and outcomes, yet they remain to be underutilized. Patient outcome
should always be at the forefront and more needs to be done to ensure that these high-risk
patients are getting the care they deserve.
Sustainability
Sustainability can be maintained by anticipating potential barriers and implementing
strategies to mitigate the barriers. For example, the likely prevalence of telemedicine visits over
face-to-face visits was anticipated in the planning stage. Because of this, time was taken to
outline a process that allowed for interventions to be achieved regardless of the type of patient
visit. However, the unexpected finding that patients did not want to participate in any face-toface office visits due to COVID-19 despite proper precautions being taken was an unanticipated
barrier. Moving the ABI testing to the wellness examination increases the likelihood that the
testing will be completed. The staff and provider were also updated regularly on how they were
performing in order to ensure transparency, open communication, and accountability. Despite
these efforts, staff were not held accountable for their performance which lead to a lack of
participation by the staff. While the project leader serves as a champion for the change process,
success of any project is dependent on the buy in, and support of the staff involved in
implementing the plan. This was a lesson learned and something that should be carefully
considered when developing a plan. This may require more face-to-face interaction with staff,
longer implementation timeline, or other various strategies to help engage those on the frontlines
to implement plans that can improve patient outcomes. One suggestion for future projects would
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be to provide staff incentives those who actively participate in implementing the plan and help to
reach the goals for the projects. This will contribute to staff empowerment and will encourage
goal-oriented behaviors. Weekly goals should be set and readily available for staff to refer to in
common areas along with current compliance information. This serves as a reminder to staff to
keep their eye on the goals. This strategy was not implemented in this project as the clinic was
small and the decision was made to provide weekly in person project updates.
The early identification and prevention of PAD complications can decrease costs for the
provider since less resources would be utilized in managing these patients with complicated
diseases processes over the long term. The time saved from having to address complications that
might otherwise have developed could be used to focus more on the management of patients’
diabetes and other comorbidities. More time could also be devoted to improving the billing of
preventative services to ensure the clinic is being properly reimbursed for the services they are
providing to their patients.
Implications for Practice
Results from this project revealed that 13% of those who had an ABI test had an
abnormal result that required a referral to a vascular specialist for further evaluation. Though the
sample size was small, this finding supports the utilization of ABI testing in the primary care
setting to identify the presence of PAD and ensure its proper treatment. The primary care
provider can help minimize complications associated with PAD by addressing risk factors.
Modifying risk factors for PAD can reduce patients’ risks of having a stroke, MI, or amputation
of the lower extremities (Virani et al., 2020). It is important to keep in mind that many of the
complications that occur with PAD develop over a period of time. Measuring the success of a
project such as this one will take time. However, it is essential to monitor patient outcomes in
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order to address areas in practice that may need specific attention in order to ensure the safety
and well-being of patients.
Clinical practice guidelines serve as a tool to help providers offer the best care possible
based on the best evidence at the time. Professional organizations help to develop these practice
recommendations based on the evidence and the collective expertise of their members. This peer
review process helps to ensure consensus on the best approach to caring for a specific patient
population. It is the expectation of the doctoral-prepared nurse practitioner to remain informed of
the most current evidence and practice guidelines and help translate this information into practice
to ensure the best patient outcomes.
Doctorate prepared advanced practice registered nurses have the knowledge, skill, and
experience to conduct quality improvement projects within healthcare systems that are patient
centered and geared to improve patient outcomes. This is done through the conduction of a
multistep system assessment. The information collected provides insight and assists in the
implementation of processes that are evidence-based and specific to a targeted population. This
project reinforces the importance of conducting a microsystem assessment, staff education,
assessment of barriers, facilitators, and the development of practice protocols for the care of
patients with DM at risk for developing PAD in the primary care setting.
Conclusion
Diabetes is a significant risk factor for PAD. Those with DM and PAD have an increased
risk of adverse cardiac and limb events, impairing the patient’s quality of life and causing longterm disability (Berger & Newman, 2020). Despite these significant and life-threatening risks,
PAD remains underdiagnosed in the primary care setting. The evidence has identified that there
is an underutilization of prevention and lifestyle counseling in patients at risk for PAD. This can
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be easily addressed through the implementation of PAD screening, ABI testing, statin and
antiplatelet utilization, diet and exercise counseling, and smoking cessation education.
Prevention is a key component of primary care, and more time should be invested in
implementing these strategies in the primary care setting in order to reduce the incidence of
disease associated patient outcomes. Even though the results from this project’s implementation
were not immediately seen for each intervention, the evidence support their continued use with
the benefits outweighing any risks. These interventions are easy to implement and are worth
considering as early identification and treatment of PAD in patients with DM and has the ability
to impact patient health, well-being, and longevity of these patients’ lives, a life that they only
get to live once. This along with time is simply invaluable.
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Appendix B:
Evidentiary Table for Summary of Evidence
Reference
Aday & Everett (2018).

Purpose

Setting

Purpose: Address Design:
some of these key Observational
outstanding
questions
Setting: 155,647
regarding the
efficacy of statin
therapy in patients
at risk of
developing PAD.

American Diabetes Association Purpose: Provide Design: N/A
(2020).
clinical guidelines
to patients with
Setting: N/A
diabetes.

Findings/Implications
Findings: Statin therapy is
underutilized in PAD patients.
Strong, intensity-dependent
association between statin therapy
and both amputation and mortality
among individuals with incident
PAD is of considerable clinical
importance.
Implications: The utilization of
statin therapy in patients with PAD
can reduce rates of amputation and
mortality. This does not only
benefit patients but physicians.
Findings: The diabetic my plate
method can be utilized to educate
and assist patients in following a
diet that assists in glycemic
control.

Quality of
Evidence
III

Level of
Evidence
B

VII

A

VII

B

VII

B

Implications: The utilization of the
diabetic my plate method will
improve glycemic control amongst
patients with diabetes and
minimize the occurrence of adverse
events secondary to diabetes.
Berger & Ladapo. (2017).

Berger & Newman (2020).

Purpose: Evaluate Design: N/A
trends in both
medical and
Sample: N/A
lifestyle counseling
for patients
diagnosed with
PAD.

Purpose: Provide
an overview of
PAD in patients
with diabetes.

Design: N/A
Setting: N/A

Findings: Secondary prevention
and lifestyle counseling are
underutilized. Patients with
peripheral vascular disease are at
risk for impaired quality of life and
significant morbidity and mortality.
The use of medical therapy and
lifestyle counseling reduces the
incidence of cardiovascular events
in PAD.
Implications: The utilization of
secondary prevention in patients
with PAD can improve patient
outcomes and quality of life.
Findings: Diabetes is a significant
risk factor for PAD that increases a
patient’s risk of developing adverse
cardiac and limb events.
Implications: N/A
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Reference
Campagna et al., (2019).

Crismaru & Diaconu (2015).

Purpose

Setting

Purpose: Discuses Design: N/A
the relationship
between diabetes
Setting: N/A
and smoking to
include
complications and
smoking cessation.

Findings: The interaction between
smoking and DM is complex.
Smoking increases risk of
cardiovascular and macrovascular
complications.

Purpose: Provide Design: Clinical
guidelines
guideline
recommendations.

Findings: The European Society of
Cardiology recommend statin
treatment for all patients with
PAD. Benefits of treatment
outweigh the risks as PAD places
patients in a high cardiovascular
risk category.

Setting: N/A

Gajanana et al. (2019).

Findings/Implications

Quality of
Evidence
VII

Level of
Evidence
B

VII

A

VII

A

VI

A

Implications: N/A

Implications: Statins are beneficial
in preventing cardiovascular events
in these patients and, due to their
pleiotropic effects, can also
increase the functional capacity
and lower the risk of adverse limb
outcome.
Findings: The FloChec digital ABI
system can be used as a valuable,
simple, cost-effective, and reliable
screening tool with high sensitivity
and accuracy.

Purpose: Provide Design:
an objective
Retrospective
analysis of the
relationship
between digital
Sample: 51
ABI and peripheral
patients with risk
Implications: These results support
angiographic data.
factors and/or
the use of digital ABI systems
symptoms of PAD
being utilized in the primary care
setting as a reliable screening tool
versus the doppler. The earlier the
diagnosis of PAD is made the
better the outcomes for the patient

Gerhard-Herman et al. (2016). Purpose: Provide
clinical practice
guidelines.
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Design: Clinical Findings: Reviews preventative
practice guideline measures such as physical activity,
diet, smoking cessation, and
stresses the importance of
Setting: N/A
managing diabetes as these
interventions slow the progression
of the disease and at times reverse
symptoms.
Implications: The AHA/ACC
recognizes that clinical decisions
involve more considerations than
evidence alone. Clinicians should
understand the evidence but
individualize decision making to
the specific patient or situation.
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Reference
Hussain et al. (2018).

John Hopkins Medicine.
(2021)

Purpose

Setting

Findings/Implications

Purpose:
Design: RCT’s
Summarize the
current available
Setting: 16 RCT’s
evidence for the
safety and efficacy
of various
antithrombotic
agents in PAD and
discuss how to
integrate this
emerging evidence
into actual clinical
practice.

Findings: Evidenced-based
approach to PAD patients is
essential to achieve optimal
outcomes, weighing cardiovascular
and limb benefits against bleeding
risks.

Purpose: Discusses Design: N/A
the key points of
PVD and PAD.
Setting: N/A

Findings: Peripheral vascular
disease can affect various blood
vessels. The goal of treatment is to
restore blood flow and prevent
disease progression with the
assistance of various therapies.
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Quality of
Evidence
I

Level of
Evidence
A

VII

B

I

B

VII

B

Implications: The use of
antithrombotic therapy can prevent
adverse cardiovascular events in
patients with PAD.

Implications: N/A

McDermott Spring, & Tian
(2021).

Neschis & Golden. (2020).

Purpose:
Design: RCT
Determine whether
low-intensity
Setting: 305
home-based
participants
walking exercise at
a comfortable pace
significantly
improves walking
ability in people
with PAD vs highintensity homebased walking
exercise vs a
nonexercised
control group.
Purpose: Provide Design: N/A
an overview of the
clinical features
Setting: N/A
and diagnosis of
PAD.

Findings: Low-intensity exercise
was significantly less effective than
high-intensity exercise and was not
significantly different from the
control.
Implications: Supervised highintensity walking exercise that
induces ischemic leg symptoms is
the first-line therapy for people
with lower-extremity peripheral
artery disease (PAD), but
adherence is poor.
Findings: PAD is a growing
problem among the aging
population and its risk factors are
like those of coronary
atherosclerosis.
Implications: N/A
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Reference
Newman et al. (2017).

Parvar et al. (2017).

Patel et al. (2018).

Purpose

Setting

Findings/Implications

Purpose: Identified
diabetes mellitus
as a coronary heart
disease risk
equivalent for
PAD.

Design: CrossFindings: Diabetes was a coronary
sectional analysis heart disease equivalent for PAD
and coronary artery stenosis.

Purpose: Reviews
evidence for the
noninvasive
management of
PAD and provides
clinical
recommendations.

Design:
Comprehensive
literature review

Purpose: Examine
smoking rates and
smoking cessation
interventions
offered to patients
with PAD and fill
knowledge gaps.

Setting: 3.5
million selfreferred
participants

Setting: N/A

Design:
Multicenter
registry
Setting: 1272
patients
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Quality of
Evidence
VII

Level of
Evidence
B

VII

A

III

A

VII

A

Implications: Screening and
prevention of peripheral vascular
disease is recommended for
patients with diabetes as it has
shown to improve outcomes.

Findings: Medical and lifestyle
management of patients with PAD
should focus on improving
outcomes and reducing
cardiovascular events to include
smoking cessation, exercise
therapy, antiplatelet therapy,
anticoagulant therapy,
antihypertensive therapy, lipidlowering therapy, and glycemic
control in patients with diabetes.
Implications: A multifactorial
approach that is methodical to each
risk factor that accounts for all
potential contributing factors is
recommended for the treatment of
PAD. Decision making should be
specific to each patient.
Findings: Patients appear to be
most likely to quit early in their
treatment course, but many quickly
relapse and 72% of all patients
smoking at baseline are still
smoking at 12 months. Better
strategies are needed to provide
continuous cessation support.
Implications: A better effort needs
to be made to offer ongoing
evidence-based smoking cessation
support in patients with PAD.

Ratchford & Khoury (2020).

Purpose: Discuss Design: Clinical
smoking cessation guideline
pathway outlined
by the ACC.
Setting: N/A

Findings: The 5 A’s framework can
assist with smoking cessation
counseling to prevent and treat all
forms of CVD.
Implications: Smoking is a
modifiable risk factor that can be
treated using the decision pathway
set by the ACC to reduce the risk
of cardiovascular events.
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Reference
Schaefer, Long, & Pollick
(2016).

Purpose
Purpose: Compare
the accuracy of the
QuantaFlo to ABI,
using primarily
duplex ultrasound
to confirm the
presence or
absence of PAD.

Setting
Design: Cohort
study

Sample: 180
patients and 360
limbs

Stanford Medicine 25. (2020). Purpose: Explain Design: N/A
ankle brachial
index
Setting: N/A
measurement,
interpretation, and
management
recommendations.

Findings/Implications
Findings: The QuantaFlo can
detect PAD with greater accuracy
then the traditional ABI.
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Quality of
Evidence
IV

Level of
Evidence
B

VII

A

VI

B

VII

A

VI

A

Implications: The QuantaFlo is
highly accurate and has the
potential to identify peripheral
vascular disease in conjunction
with physical exam and patient
history. The use of this tool can
improve the in-office diagnosis of
PAD and encourage early
identification.
Findings: ABI has been shown to
predict mortality and adverse
cardiovascular events independent
of traditional CV risk factors and is
recommended in every smoker
over 50 years old, every diabetic
over 50, and all patients over 70.
Implications: The correct ABI
measurement can assist in the
reliable diagnosis of PAD and
ensure early identification of the
disease process.

Tóth-Vajna et al. (2019).

Purpose: Improve Design:
the efficiency of Observational
primary health care
screening in PAD
Sample: 816
and reduce the
extremely high
domestic
amputation ratio.

Findings: Peripheral artery disease
is diagnosed late in the primary
care setting. Screening with ABI
has a sensitivity and specificity
between 79%-96%.
Implications: The early detection
of PAD in primary care
significantly improves patient
quality of life and life expectancy.

U.S. Preventive Services Task Purpose: Clinical Design: Clinical Findings: The USPSF concludes
Force. (2017).
practice guideline. practice guideline that the current evidence is
insufficient to assess the balance of
benefits and harms of screening for
Setting: N/A
PAD and CVD risk with the anklebrachial index in asymptomatic
adults.

Virani et al. (2020).

Purpose: Provide
clinical practice
guidelines.

Implications: The USPSF
recognizes that clinical decisions
involve more considerations than
evidence alone. Clinicians should
understand the evidence but
individualize decision making to
the specific patient or situation.
Design: Clinical Findings: Guidelines address
practice guidelines peripheral artery disease and are a
reference utilized by healthcare
providers to care for patients at risk
Setting: N/A
based on the most recent evidence
provided by this organization.
Implications: The AHA recognizes
that clinical decisions involve more
considerations than evidence alone.
Clinicians should understand the
evidence but individualize decision
making to the specific patient or
situation.
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